

# Clinical trials of mTOR inhibitor for advanced breast cancer (metastatic) in first line therapy

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 combination with endocrine therapy

Trial	Treatments	Patients	Trials design and methods
<b>temsirolimus + letrozole vs letrozole alone</b>			
<b>HORIZON , 2013</b> [NCT00083993] n=556/556 follow-up:	oral letrozole 2.5 mg daily/temsirolimus 30 mg daily (5 days every 2 weeks) versus letrozole/placebo	first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer	Parallel groups double-blind

## References

### HORIZON, 2013:

Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincaat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31:195-202 [[23233719](#)]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.